Evaluating Blood-Material Interactions
Hemocompatibility refers to the ability of a medical device or material to perform in contact with blood without inducing adverse reactions such as thrombosis, hemolysis, or immune system activation. Guided by ISO 10993-4, this assessment is mandatory for any device that has direct or indirect contact with the cardiovascular system.
1. The Five Pillars of Evaluation
ISO 10993-4 categorizes blood-material interactions into five key areas:
-
Thrombosis: Evaluates the tendency of the device to induce blood clots at the surface.
-
Coagulation: Determines if the material extends or accelerates the natural clotting cascade.
-
Platelet Interactions: Measures platelet adhesion, aggregation, and activation state.
-
Hematology: Includes the critical Hemolysis Test, which measures the rupture of red blood cells and the release of free hemoglobin.
-
Complement System: Assesses the activation of the complement pathway, a key part of the innate immune response (e.g., measuring SC5b-9).
2. Integration with ASTM Standards
While ISO provides the framework, ASTM standards offer specific experimental protocols:
-
ASTM F756: Standard Practice for Assessment of Hemolytic Properties (Static and Dynamic methods).
-
ASTM F2382: Standard Test Method for Assessment of Circulating Complement Activation.
-
ASTM F2888: Standard Test Method for Platelet Leukocyte Count.
3. Clinical Relevance: Static vs. Dynamic Testing
For devices intended for use in high-flow environments, such as stents or oxygenators, Dynamic Loop Studies are often required. These simulations provide a more realistic representation of how a device will behave under physiological blood flow conditions compared to simple static immersion.
Click to Pay
